Anti-cancer activities of Ganoderma lucidum: Active ingredients and pathways

Functional Foods in Health and Disease

Volumn 3, Issue 2, 2013, Pages 48-65

  Kao, Chi H J ^a   Jesuthasan, Amalini C ^a   Bishop, Karen S ^b   Glucina, Marcus P ^c   Ferguson, Lynnette R ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Great Navy Ltd   (New Zealand)

Author keywords

Bioactive pathways; Cancer; Ganoderma lucidum; Polysaccharide; Triterpene

Indexed keywords

EID: 84898435101     PISSN: 23787007     EISSN: 21603855     Source Type: Journal    
DOI: 10.31989/ffhd.v3i2.65     Document Type: Review

References (101)

1. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, Bisen PS: Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol. 2009, 10(8):717-742.
2. Mau JL, Lin HC, Chen CC: Non-volatile components of several medicinal mushrooms. Food Research International. 2001, 34(6):521-526.
3. Boh B, Berovic M, Zhang J, Zhi-Bin L: Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev. 2007, 13:265-301.
4. Zhou XW, Lin J, Yin YZ, Zhao JY, Sun XF, Tang KX: Ganodermataceae: Natural products and their related pharmacological functions. American Journal of Chinese Medicine. 2007, 35(4):559-574.
5. Yuen JW, Gohel MD: Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer. 2005, 53(1):11-17.
6. Shi L, Ren A, Mu D, Zhao M: Current progress in the study on biosynthesis and regulation of ganoderic acids. Appl Microbiol Biotechnol. 2010, 88(6):1243-1251.
7. Haralampidis K, Trojanowska M, Osbourn AE: Biosynthesis of triterpenoid saponins in plants. Adv Biochem Eng Biotechnol. 2002, 75:31-49.
8. Yue QX, Song XY, Ma C, Feng LX, Guan SH, Wu WY, Yang M, Jiang BH, Liu X, Cui YJ, Guo DA: Effects of triterpenes from Ganoderma lucidum on protein expression profile of HeLa cells. Phytomedicine: international journal of phytotherapy and phytopharmacology. 2010, 17(8-9):606-613.
9. Su CH, Yang YZ, Ho HO, Hu CH, Sheu MT: High-performance liquid chromatographic analysis for the characterization of triterpenoids from Ganoderma. J Chromatogr Sci. 2001, 39(3):93-100.
10. Chen NH, Liu JW, Zhong JJ: Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression. Pharmacol Rep. 2010, 62(1):150-163.
11. Tang W, Liu JW, Zhao WM, Wei DZ, Zhong JJ: Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci. 2006, 80(3):205-211.
12. Xu K, Liang X, Gao F, Zhong J, Liu J: Antimetastatic effect of ganoderic acid T in vitro through inhibition of cancer cell invasion. Process Biochemistry. 2010, 45(8):1261-1267.
13. Yue QX, Cao ZW, Guan SH, Liu XH, Tao L, Wu WY, Li YX, Yang PY, Liu X, Guo DA: Proteomics characterization of the cytotoxicity mechanism of ganoderic acid D and computer-automated estimation of the possible drug target network. Mol Cell Proteomics. 2008, 7(5):949-961.
14. Chang UM, Li CH, Lin LI, Huang CP, Kan LS, Lin SB: Ganoderiol F, a ganoderma triterpene, induces senescence in hepatoma HepG2 cells. Life sciences. 2006, 79(12):1129-1139.
15. Min BS, Gao JJ, Nakamura N, Hattori M: Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells. Chemical & pharmaceutical bulletin. 2000, 48(7):1026-1033.
16. Gao JJ, Min BS, Ahn EM, Nakamura N, Lee HK, Hattori M: New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chemical & pharmaceutical bulletin. 2002, 50(6):837-840.
17. Gao JJ, Hirakawa A, Min BS, Nakamura N, Hattori M: In vivo antitumor effects of bitter principles from the antlered form of fruiting bodies of Ganoderma lucidum. Journal of Natural Medicines. 2006, 60(1):42-48.
18. Guan SH, Xia JM, Yang M, Wang XM, Liu X, Guo DA: Cytotoxic lanostanoid triterpenes from Ganoderma lucidum. Journal of Asian natural products research. 2008, 10(7-8):705-710.
19. Niu XM, Li SH, Xiao WL, Sun HD, Che CT: Two new lanostanoids from Ganoderma resinaceum. Journal of Asian natural products research. 2007, 9(6-8):659-664.
20. Patra N, De U, Kang JA, Kim JM, Ahn MY, Lee J, Jung JH, Chung HY, Moon HR, Kim HS: A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. Eur J Pharmacol. 2011, 658(2-3):98-107.
21. Wu G, Qian Z, Guo J, Hu D, Bao J, Xie J, Xu W, Lu J, Chen X, Wang Y: Ganoderma lucidum Extract Induces G1 Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells. Am J Chin Med. 2012, 40(3):631-642.
22. Jedinak A, Thyagarajan-Sahu A, Jiang J, Sliva D: Ganodermanontriol, a lanostanoid triterpene from Ganoderma lucidum, suppresses growth of colon cancer cells through sscatenin signaling. Int J Oncol. 2011, 38(3):761-767.
23. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'amico M, Pestell R, Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999, 96(10):5522-5527.
24. Yan YX, Nakagawa H, Lee MH, Rustgi AK: Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cisregulatory element in the cyclin D1 promoter. J Biol Chem. 1997, 272(52):33181-33190.
25. Tetsu O, Mccormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999, 398(6726):422-426.
26. Bartkova J, Lukas J, Strauss M, Bartek J: The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer. 1994, 58(4):568-573.
27. Lin SB, Li CH, Lee SS, Kan LS: Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci. 2003, 72(21):2381-2390.
28. Thompson LJ, Fields AP: betaII protein kinase C is required for the G2/M phase transition of cell cycle. J Biol Chem. 1996, 271(25):15045-15053.
29. Fishman DD, Segal S, Livneh E: The role of protein kinase C in G1 and G2/M phases of the cell cycle (review). Int J Oncol. 1998, 12(1):181-186.
30. Arita Y, Buffolino P, Coppock DL: Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity. Exp Cell Res. 1998, 242(2):381-390.
31. Hofmann J, O'connor PM, Jackman J, Schubert C, Ueberall F, Kohn KW, Grunicke H: The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochem Biophys Res Commun. 1994, 199(2):937-943.
32. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002, 298(5600):1911-1912.
33. Liu Y, Guyton KZ, Gorospe M, Xu Q, Lee JC, Holbrook NJ: Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic Biol Med. 1996, 21(6):771-781.
34. Price MA, Cruzalegui FH, Treisman R: The p38 and ERK MAP kinase pathways cooperate to activate Ternary Complex Factors and c-fos transcription in response to UV light. EMBO J. 1996, 15(23):6552-6563.
35. Li CH, Chen PY, Chang UM, Kan LS, Fang WH, Tsai KS, Lin SB: Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells. Life sciences. 2005, 77(3):252-265.
36. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D: Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer. 2004, 49(2):209-216.
37. Fukuzawa M, Yamaguchi R, Hide I, Chen Z, Hirai Y, Sugimoto A, Yasuhara T, Nakata Y: Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biol Pharm Bull. 2008, 31(10):1933-1937.
38. Liu RM, Zhong JJ: Ganoderic acid Mf and S induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells. Phytomedicine: international journal of phytotherapy and phytopharmacology. 2011, 18(5):349-355.
39. Liu RM, Li YB, Zhong JJ: Cytotoxic and pro-apoptotic effects of novel ganoderic acid derivatives on human cervical cancer cells in vitro. Eur J Pharmacol. 2012, 681(1-3):23-33.
40. Green DR, Reed JC: Mitochondria and apoptosis. Science. 1998, 281(5381):1309-1312.
41. Green D, Kroemer G: The central executioners of apoptosis: caspases or mitochondria? Trends in cell biology. 1998, 8(7):267-271.
42. Liu RM, Zhong JJ: Ganoderic acid Mf and S induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells. Phytomedicine. 2011, 18(5):349-355.
43. Zimmermann KC, Green DR: How cells die: apoptosis pathways. The Journal of allergy and clinical immunology. 2001, 108(4 Suppl):S99-103.
44. Zong WX, Li C, Hatzivassiliou G, Lindsten T, Yu QC, Yuan J, Thompson CB: Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol. 2003, 162(1):59-69.
45. Tzivion G, Gupta VS, Kaplun L, Balan V: 14-3-3 proteins as potential oncogenes. Seminars in cancer biology. 2006, 16(3):203-213.
46. Masters SC, Yang H, Datta SR, Greenberg ME, Fu H: 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Molecular pharmacology. 2001, 60(6):1325-1331.
47. Bielawski K, Bielawska A, Slodownik T, Bolkun-Skornicka U, Muszynska A: Prolinelinked nitrosoureas as prolidase-convertible prodrugs in human breast cancer cells. Pharmacological reports: PR. 2008, 60(2):171-182.
48. Chen NH, Liu JW, Zhong JJ: Ganoderic acid Me inhibits tumor invasion through down-regulating matrix metalloproteinases 2/9 gene expression. Journal of pharmacological sciences. 2008, 108(2):212-216.
49. Chen NH, Liu JW, Zhong JJ: Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression. Pharmacological reports: PR. 2010, 62(1):150-163.
50. Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R: Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000, 60(22):6298-6302.
51. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G: IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene. 2003, 22(2):256-265.
52. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ: Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer research. 2002, 62(19):5571-5579.
53. Thyagarajan A, Jiang J, Hopf A, Adamec J, Sliva D: Inhibition of oxidative stress-induced invasiveness of cancer cells by Ganoderma lucidum is mediated through the suppression of interleukin-8 secretion. Int J Mol Med. 2006, 18(4):657-664.
54. Birbach A, Eisenbarth D, Kozakowski N, Ladenhauf E, Schmidt-Supprian M, Schmid JA: Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia. 2011, 13(8):692-703.
55. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007, 7(4):256-269.
56. Lin CY, Lin CJ, Chen KH, Wu JC, Huang SH, Wang SM: Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett. 2006, 580(13):3042-3050.
57. Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, Kohno K, Umezawa K, Iguchi H, Shirouzu K, Takamori S, Kuwano M, Ono M: Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci. 2007, 98(12):2009-2018.
58. Dudhgaonkar S, Thyagarajan A, Sliva D: Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol. 2009, 9(11):1272-1280.
59. Dreher D, Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer. 1996, 32A(1):30-38.
60. Sun J, Chu YF, Wu X, Liu RH: Antioxidant and antiproliferative activities of common fruits. J Agric Food Chem. 2002, 50(25):7449-7454.
61. Smina TP, Mathew J, Janardhanan KK, Devasagayam TP: Antioxidant activity and toxicity profile of total triterpenes isolated from Ganoderma lucidum (Fr.) P. Karst occurring in South India. Environ Toxicol Pharmacol. 2011, 32(3):438-446.
62. Smina TP, De S, Devasagayam TP, Adhikari S, Janardhanan KK: Ganoderma lucidum total triterpenes prevent radiation-induced DNA damage and apoptosis in splenic lymphocytes in vitro. Mutat Res. 2011, 726(2):188-194.
63. Chan W, Law H, Lin Z, Lau Y, Chan G: Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley. International Immunology. 2007, 19(7):891-899.
64. Sone Y, Okuda R, Wada N, Kishida E, Misaki A: Structure and antitumor activities of polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agric Biol Chem. 1985, 49:2641-2653.
65. Upton R, Pharmacopoeia AH. Reishi Mushroom: Ganoderma Lucidum: Standards of Analysis, Quality Control, and Therapeutics: American Herbal Pharmacopoeia; 2000.
66. Chen WC, Hau DM, Lee SS: Effects of Ganoderma-Lucidum and Krestin on Cellular Immunocompetence in Gamma-Ray-Irradiated Mice. American Journal of Chinese Medicine. 1995, 23(1):71-80.
67. Lieu CW, Lee SS, Wang SY: The Effect of Ganoderma-Lucidum on Induction of Differentiation in Leukemic U937-Cells. Anticancer Research. 1992, 12(4):1211-1216.
68. Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, Ho CK: The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. International Journal of Cancer. 1997, 70(6):699-705.
69. Chang ST. Mushrooms cultivation, nutritional value, medicinal effect, and environmental impact. Miles PG, Chang ST, editors. Boca Raton, Fla.: Boca Raton, Fla: CRC Press; 2004.
70. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M: The Role of Macrophage Inhibitory Factor in Tumorigenesis and Central Nervous System Tumors. Cancer. 2009, 115(10):2031-2040.
71. Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current Opinion in Immunology. 2010, 22(2):231-237.
72. Zhang J, Tang Q, Zhou C, Jia W, Da Silva L, Nguyen LD, Reutter W, Fan H: GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response. Life sciences. 2010, 87(19-22):628-637.
73. Hewitt EW: The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 2003, 110(2):163-169.
74. Gebhard B, Schutz G, Ecker RC, Steiner GE, Rudas M, Gnant M, Oehler R: MHC-class-I expression in human breast cancer correlates with nuclear localization of the 90 kDa heat-shock-protein. Anticancer research. 1999, 19(6B):5293-5297.
75. Kijima M, Saio M, Oyang GF, Suwa T, Miyauchi R, Kojima Y, Imai H, Nakagawa J, Nonaka K, Umemura N, Nishimura T, Takami T: Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. International journal of oncology. 2005, 26(3):679-684.
76. Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH, Lin CH: Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: Functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorganic & Medicinal Chemistry. 2002, 10(4):1057-1062.
77. Chien CA, Cheng JL, Chang WT, Tien MH, Tsao CM, Chang YH, Chang HY, Hsieh JF, Wong CH, Chen ST: Polysaccharides of Ganoderma lucidum alter cell immunophenotypic expression and enhance CD56(+) NK-cell cytotoxicity in cord blood. Bioorganic & Medicinal Chemistry. 2004, 12(21):5603-5609.
78. Hsu JW, Huang HC, Chen ST, Wong CH, Juan HF: Ganoderma lucidum Polysaccharides Induce Macrophage-Like Differentiation in Human Leukemia THP-1 Cells via Caspase and p53 Activation. Evid Based Complement Alternat Med. 2011, 2011:358717.
79. Lin KM, Austin GE: Functional activity of three distinct myeloperoxidase (MPO) promoters in human myeloid cells. Leukemia. 2002, 16(6):1143-1153.
80. Lu HM, Uesaka T, Katoh O, Kyo E, Watanabe H: Prevention of the development of preneoplastic lesions, aberrant crypt foci, by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male F344 rats. Oncol Rep. 2001, 8(6):1341-1345.
81. Lu H, Kyo E, Uesaka T, Katoh O, H. W: A water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep. 2003, 10(2):375-379.
82. Lee JM, Kwon H, Jeong H, Lee JW, Lee SY, Baek SJ, Surh YJ: Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res. 2001, 15(3):245-249.
83. Song YS, Kim SH, Sa JH, Jin C, Lim CJ, Park EH: Anti-angiogenic and inhibitory activity on inducible nitric oxide production of the mushroom Ganoderma lucidum. Journal of ethnopharmacology. 2004, 90(1):17-20.
84. Cao QZ, Lin ZB: Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sciences. 2006, 78(13):1457-1463.
85. Stanley G, Harvey K, Slivova V, Jiang J, Sliva D: Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochemical and biophysical research communications. 2005, 330(1):46-52.
86. Ruhan Askin MS, And Motonobu Goto*: Extraction of bioactive compounds from Ganoderma Lucidum. Department of Applied Chemistry and Biochemistry, Kumamoto University. 2008.
87. Zhou XW, Su KQ, Zhang YM: Applied modern biotechnology for cultivation of Ganoderma and development of their products. Applied Microbiology and Biotechnology. 2012, 93(3):941-963.
88. Huang SQ, Li JW, Wang Z, Pan HX, Chen JX, Ning ZX: Optimization of Alkaline Extraction of Polysaccharides from Ganoderma lucidum and Their Effect on Immune Function in Mice. Molecules. 2010, 15(5):3694-3708.
89. Gao Y, Zhou S: Cancer Prevention and Treatment by Ganoderma, a Mushroom with Medicinal Properties. Food Reviews International. 2003, 19(3):275-325.
90. Gao Y, Zhang R, Zhang J, Gao S, Gao W, Zhang H, Wang H, Han B: Study of the extraction process and in vivo inhibitory effect of ganoderma triterpenes in oral mucosa cancer. Molecules. 2011, 16(7):5315-5332.
91. Lu QY, Jin YS, Zhang QF, Zhang ZF, Heber D, Go VLW, Li FP, Rao JY: Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. Cancer Lett. 2004, 216(1):9-20.
92. Tong CC, Choong YK, Umar NaB, Noordin MM, Mohamed S: Cytotoxic activity induced by crude extracts of Ganoderma lucidum (W. Curt.: Fr.) P. Karst. on mouse myeloma cancer cell-line. World Journal of Microbiology & Biotechnology. 2009, 25(4):687-695.
93. Pillai TG, Savi VP, Maurya DK, Nair CKK, Janardhanan KK: Prevention of radiation-induced damages by aqueous extract of Ganoderma lucidum occurring in southern parts of India. Current Science. 2006, 91(3):341-344.
94. Smina TP, Mathew J, Janardhanan KK, Deuasagayam TPA: Antioxidant activity and toxicity profile of total triterpenes isolated from Ganoderma lucidum (Fr.) P. Karst occurring in South India. Environmental Toxicology and Pharmacology. 2011, 32(3):438-446.
95. Chen WC, Hau DM: Effects of Ganoderma-Lucidum on Cellular Immunocompetence in Gamma-Irradiated Mice. Phytotherapy Research. 1995, 9(7):533-535.
96. Smina TP, De S, Devasagayam TPA, Adhikari S, Janardhanan KK: Ganoderma lucidum total triterpenes prevent radiation-induced DNA damage and apoptosis in splenic lymphocytes in vitro. Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 2011, 726(2):188-194.
97. Chen WC, Hau DM, Wang CC, Lin IH, Lee SS: Effects of Ganoderma-Lucidum and Krestin on Subset T-Cell in Spleen of Gamma-Irradiated Mice. American Journal of Chinese Medicine. 1995, 23(3-4):289-298.
98. Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A: Cisplatin-Induced Renal Salt Wasting Syndrome. Southern Medical Journal. 2010, 103(8):793-799.
99. Sheena N, Ajith TA, Janardhanan KK: Prevention of nephrotoxicity induced by the anticancer drug cisplatin, using Ganoderma lucidum, a medicinal mushroom occurring in South India. Current Science. 2003, 85(4):478-482.
100. Somani SM, Husain K, Whitworth C, Trammell GL, Malafa M, Rybak LP: Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: Antioxidant defense system. Pharmacology & Toxicology. 2000, 86(5):234-241.
101. Hanaoka R, Ueno Y, Tanaka S, Nagai K, Onitake T, Yoshioka K, Chayama K: The water-soluble extract from cultured medium of Ganoderma lucidum (Reishi) mycelia (Designated as MAK) ameliorates murine colitis induced by trinitrobenzene sulphonic acid. Scand J Immunol. 2011, 74(5):454-462.